Floatz logo

Atezolizumab

MSI

Vall d'Hebron Institute of Oncologymonoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the MSI cohort.

Asset / SponsorPhaseRating
Eloxatin
Federation Francophone de Cancerologie Digestive
Phase 2B
PANITUMUMAB
Federation Francophone de Cancerologie Digestive
Phase 2B
Calcium folinate pentahydrate
Federation Francophone de Cancerologie Digestive
Phase 2B
Cetuximab
Federation Francophone de Cancerologie Digestive
Phase 2B
(+)-VINCRISTINE
Federation Francophone de Cancerologie Digestive
Phase 2B

View all 12 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Stage IV Lung Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →